Anticipated cash available for use by the Company
is A$9.5 million. During fiscal year 2019, we expect a decrease in net quarterly cash outlays resulting
from the conclusion of our FDA clinical trial, inflows from customers on product sales, and cost savings following certain cost reduction measures taken by the Company, including closure of its Melbourne office and reductions in staffing.
I don't think we're in danger of any CR at all.
Most of the expenses were one offs so out goings this quarter should be significantly less. There was a mention of income from their commercial customers. I would like to see these figures in more detail.
I just hope Jack will announce new contracts as they sign on.
MEB Price at posting:
20.5¢ Sentiment: Buy Disclosure: Held
